Key result
Immune checkpoint inhibitors linked to ~101% higher risk of arterial thromboembolic events vs non-ICI therapy.
Why the study?
Immune checkpoint inhibitors are standard treatments for various malignancies, but blocking this pathway may exacerbate atherosclerotic lesions, prompting investigation into whether ICI therapy increases arterial thromboembolic event risk.
Does immune checkpoint inhibitor therapy increase the risk of arterial thromboembolic events in cancer patients?
Cohort
No
Does immune checkpoint inhibitor therapy increase the risk of arterial thromboembolic events in cancer patients?
Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitor therapy in cancer patients is associated with a significantly increased risk of arterial thromboembolic events, particularly after one year of treatment.
BACKGROUND: Immune checkpoint inhibitors (ICIs) have emerged as a standard treatment for various malignancies. However, research indicates blocking the immune checkpoint pathway may exacerbate atherosclerotic lesions. OBJECTIVES: We aimed to investigate whether ICI therapy increases the risk of arterial thromboembolic events (ATEs). METHODS: A retrospective cohort study was conducted on patients with histologically confirmed cancer at our institution between 2018 and 2021, using the propensity score matching method. The primary endpoint was ATEs occurrence, comprising acute coronary syndrome, stroke/transient ischemic attack, and peripheral arterial thromboembolism. Subgroup analyses assessed whether the ICI treatment effect on ATEs varied over time by limiting the maximum follow-up duration. Logistic regression analysis identified ATE risk factors in ICI-treated patients. RESULTS: Overall, the ICI group (n = 2877) demonstrated an ATEs risk 2.01 times higher than the non-ICI group (RR, 2.01 [95% CI (1.61-2.51)]; p < 0.001). Subgroup analysis revealed no significant increase in ATEs risk for ICI-treated patients within 1 year (Limited to a max 9-month follow-up, p = 0.075). However, ATEs risk in the ICI group rose by 41% at 1 year (p = 0.010) and 97% at 4 years (p ≤ 0.001). Age, diabetes, hypertension, peripheral atherosclerosis, atrial fibrillation, chronic ischemic heart disease, distant cancer metastasis, and ICI treatment cycles contributed to ATEs risk elevation in ICI-treated patients. CONCLUSION: ICI-treated patients may exhibit a higher risk of ATEs, especially after 1 year of treatment.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2023) conducted a cohort in Cancer. Immune checkpoint inhibitors (ICIs) vs. Non-ICI therapy was evaluated on Arterial thromboembolic events (ATEs) occurrence, comprising acute coronary syndrome, stroke/transient ischemic attack, and peripheral arterial thromboembolism (RR 2.01, 95% CI 1.61-2.51, p=< 0.001). Immune checkpoint inhibitor therapy in cancer patients was associated with a significantly higher risk of arterial thromboembolic events compared to non-ICI therapy (RR 2.01; 95% CI 1.61-2.51; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: